Filing Flows › HCW Biologics (HCWB) › Q2 2026
HCW Biologics (HCWB) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
HCW Biologics (HCWB) reported revenue of $136K for the second quarter 2026 (Q2 2026), up 21-fold from a year earlier and -98% from the quarter before.
HCW Biologics, Q2 2026: revenue $136K (21× year over year), net loss $5.2M, operating cash flow −$4.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $136K | -98% | 21× |
| Operating profit | −$3.2M | -198% | — |
| Net earnings | −$5.2M | -250% | — |
| Operating cash flow | −$4.0M | — | — |
What changed
Revenue was $136K in Q2 2026, up 1970% year over year and down 98% from the previous quarter.
Operating costs exceeded revenue by $3.2M, an operating margin of -2335.6%. The quarter ended with a net loss of $5.2M, after a profit of $3.5M the previous quarter.
Operating cash flow was −$4.0M. Non-cash charges added back $127K of depreciation and amortization and $1K of share-based compensation. Working capital and other items added $1.1M.
Questions
What was HCW Biologics' revenue in the second quarter 2026?
HCW Biologics (HCWB) reported revenue of $136K for the second quarter 2026 (Q2 2026), up 21-fold from a year earlier and -98% from the quarter before.
Source: HCW Biologics 10-Q on SEC EDGAR.